Bessemer Group Inc. Grows Position in Illumina, Inc. (NASDAQ:ILMN)

Bessemer Group Inc. increased its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 32,837.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,348,131 shares of the life sciences company's stock after purchasing an additional 1,344,038 shares during the quarter. Bessemer Group Inc. owned approximately 0.85% of Illumina worth $180,152,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. Versant Capital Management Inc grew its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares in the last quarter. Golden State Wealth Management LLC bought a new position in Illumina in the fourth quarter valued at about $32,000. Assetmark Inc. raised its stake in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Illumina in the fourth quarter worth about $45,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Illumina in the 4th quarter valued at approximately $48,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Citigroup cut their price objective on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Canaccord Genuity Group lowered their target price on Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a report on Tuesday, March 11th. Stephens restated an "overweight" rating and set a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. Finally, TD Cowen cut shares of Illumina from a "buy" rating to a "hold" rating and decreased their price target for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $138.70.

Remove Ads

Illumina Stock Down 0.1 %

Illumina stock traded down $0.08 during mid-day trading on Monday, reaching $74.70. The stock had a trading volume of 980,394 shares, compared to its average volume of 2,263,061. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The stock's 50-day simple moving average is $88.58 and its 200-day simple moving average is $122.25. The firm has a market capitalization of $11.83 billion, a PE ratio of -9.73, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.